KRYSTAL-1: Two Year Follow Up of Adagrasib Monotherapy in Patients With Advanced/Metastatic KRAS G12C Mutated NSCLC

Opinion
Video

A review of adagrasib in the KRYSTAL-1 trial in patients with NSCLC.

Recent Videos
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
Video 4 - "Frontline Treatment for EGFR-Mutated Lung Cancer"
Related Content
Surufatinib/Toripalimab Shows Encouraging Activity in NSCLC and SCLC

Surufatinib/Toripalimab Shows Encouraging Activity in NSCLC and SCLC

Tim Cortese
April 8th 2025
Article

Surufatinib/toripalimab elicited an ORR of 57.1% in patients with treatment-naïve NSCLC and 15.8% in patients with pretreated SCLC in a phase 2 trial.

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Exploring the Value of Preoperative CAPTEM in Atypical Lung NETs

Georgios Evangelou, MD, MSc
September 16th 2024
Podcast

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

AI, Immunotherapy, More Key Lung Cancer Advances Highlighted at 2025 ELCC

AI, Immunotherapy, More Key Lung Cancer Advances Highlighted at 2025 ELCC

Ariana Pelosci
April 1st 2025
Article

An expert panel at ELCC 2025 reviews the MARIPOSA trial's implications for first-line therapy in EGFR-mutated NSCLC and broader advancements.

Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.

Achieving Health Equity in Lung Cancer Surgery

Rian M. Hasson Charles, MD, MPH, FACS
April 1st 2024
Podcast

Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.

Patients with driver gene–negative non–small cell lung cancer who received immunotherapy beyond progression experienced better survival outcomes.

Continuous Second-Line Immunotherapy May Benefit Pretreated Lung Cancer

Roman Fabbricatore
March 6th 2025
Article

Patients with driver gene–negative non–small cell lung cancer who received immunotherapy beyond progression experienced better survival outcomes.

AI/ML-Based Software Improves Diagnostic Accuracy in Lung Cancer

AI/ML-Based Software Improves Diagnostic Accuracy in Lung Cancer

Tim Cortese
February 5th 2025
Article

The diagnostic accuracy of radiologists aided by the eyonis LCS AI software was greatly improved compared with when radiologists were unaided.